{"transactions":[{"id":700527,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-07-30T20:34:01.000Z","date":"2026-07-28","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027."}],"balance_after":56102,"source":{"system":"sec-edgar","filing":"0001437749-26-025082","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774926025082/rdgdoc.xml","form_type":"4"}},{"id":964825,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:00:18.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1155,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":3.453,"underlying":"Common Stock","underlying_shares":1155},"source":{"system":"sec-edgar","filing":"0001193125-25-322646","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322646/ownership.xml","form_type":"4"}},{"id":964824,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-17T16:00:18.000Z","date":"2025-12-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5833,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the \"Merger Agreement\"), by and among the Issuer, QOL Medical, LLC (\"Parent\") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Company Option\") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":5.26,"underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0001193125-25-322646","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000119312525322646/ownership.xml","form_type":"4"}},{"id":1021997,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-10-07T20:16:28.000Z","date":"2025-10-03","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027."}],"balance_after":36102,"source":{"system":"sec-edgar","filing":"0001437749-25-030650","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925030650/rdgdoc.xml","form_type":"4"}},{"id":1136923,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T17:00:16.000Z","date":"2025-05-21","kind":"grant","planned":false,"acquired":true,"shares":1155,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The total number of shares of common stock subject to the option vests on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":6988,"derivative":{"exercise_price":3.453,"expiration_date":"2035-05-20","underlying":"Common Stock","underlying_shares":1155},"source":{"system":"sec-edgar","filing":"0000950170-25-076435","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017025076435/ownership.xml","form_type":"4"}},{"id":1187765,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-31T20:34:24.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0001437749-25-010224","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925010224/rdgdoc.xml","form_type":"4"}},{"id":1187764,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2025-03-31T20:34:24.000Z","date":"2025-03-31","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23602,"source":{"system":"sec-edgar","filing":"0001437749-25-010224","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774925010224/rdgdoc.xml","form_type":"4"}},{"id":1249344,"issuer":{"id":71094,"kind":"organization","name":"Evoke Pharma Inc","symbol":"EVOK"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-24T17:03:16.000Z","date":"2025-02-20","kind":"grant","planned":false,"acquired":true,"shares":5833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the total number of shares of common stock subject to the option shall vest following each one-year period after February 20, 2025, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date, so that the option shall be fully vested on the third anniversary of the date of grant."}],"balance_after":5833,"derivative":{"exercise_price":5.26,"expiration_date":"2035-02-19","underlying":"Common Stock","underlying_shares":5833},"source":{"system":"sec-edgar","filing":"0000950170-25-025771","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1403708/000095017025025771/ownership.xml","form_type":"4"}},{"id":1318365,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-02T22:02:47.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":209,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-25-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225000018/form4.xml","form_type":"4"}},{"id":1318364,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2025-01-02T22:02:47.000Z","date":"2024-12-31","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23393,"source":{"system":"sec-edgar","filing":"0000912282-25-000018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228225000018/form4.xml","form_type":"4"}},{"id":1371036,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-11-09T00:23:40.000Z","date":"2024-11-06","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025."}],"balance_after":7000,"derivative":{"exercise_price":1.84,"expiration_date":"2034-11-06","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-24-000750","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000750/form4.xml","form_type":"4"}},{"id":1393838,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-02T21:18:57.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":417,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0000912282-24-000682","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000682/form4.xml","form_type":"4"}},{"id":1393837,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-10-02T21:18:57.000Z","date":"2024-09-30","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":23185,"source":{"system":"sec-edgar","filing":"0000912282-24-000682","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000682/form4.xml","form_type":"4"}},{"id":1462265,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-02T21:20:16.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":626,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-24-000527","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000527/form4.xml","form_type":"4"}},{"id":1462264,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-07-02T21:20:16.000Z","date":"2024-06-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":22976,"source":{"system":"sec-edgar","filing":"0000912282-24-000527","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000527/form4.xml","form_type":"4"}},{"id":1552872,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-02T20:44:18.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":834,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-24-000340","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000340/form4.xml","form_type":"4"}},{"id":1552871,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-04-02T20:44:18.000Z","date":"2024-03-31","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025."}],"balance_after":22768,"source":{"system":"sec-edgar","filing":"0000912282-24-000340","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000340/form4.xml","form_type":"4"}},{"id":1696127,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-02T21:37:59.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":false,"shares":209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1042,"derivative":{"underlying":"Common Shares","underlying_shares":209},"source":{"system":"sec-edgar","filing":"0000912282-24-000006","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000006/form4.xml","form_type":"4"}},{"id":1696126,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2024-01-02T21:37:59.000Z","date":"2023-12-31","kind":"exercise","planned":false,"acquired":true,"shares":209,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22560,"source":{"system":"sec-edgar","filing":"0000912282-24-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228224000006/form4.xml","form_type":"4"}},{"id":1766695,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-10-03T20:37:00.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1251,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-23-000399","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000399/form4.xml","form_type":"4"}},{"id":1766694,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Common Shares","published_at":"2023-10-03T20:37:00.000Z","date":"2023-09-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22351,"source":{"system":"sec-edgar","filing":"0000912282-23-000399","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000399/form4.xml","form_type":"4"}},{"id":1807063,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commercial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-08-15T23:21:18.000Z","date":"2023-08-11","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 1/3 on August 11, 2024, with the remaining options vesting in 24 equal monthly installments beginning September 11, 2024."}],"balance_after":7000,"derivative":{"exercise_price":1.73,"expiration_date":"2033-08-12","underlying":"Common Shares","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000912282-23-000295","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000295/form4.xml","form_type":"4"}},{"id":1833565,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-07-06T19:26:53.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":false,"shares":208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":1459,"derivative":{"underlying":"Common Shares","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0000912282-23-000164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000164/form4.xml","form_type":"4"}},{"id":1833564,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-07-06T19:26:53.000Z","date":"2023-06-30","kind":"exercise","planned":false,"acquired":true,"shares":208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."}],"balance_after":22143,"source":{"system":"sec-edgar","filing":"0000912282-23-000164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000164/form4.xml","form_type":"4"}},{"id":1849007,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-06-20T12:35:10.000Z","date":"2023-06-16","kind":"purchase","planned":false,"acquired":true,"shares":12000,"price":1.869,"value":22428.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported in Column 4 above is an average weighted price.  These shares were purchased in multiple transactions at prices ranging from $1.84 to $1.869, inclusive.  The reporting person undertakes to provide to AYTU Biopharma, Inc., any security holder of AYTU Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":21935,"source":{"system":"sec-edgar","filing":"0000912282-23-000137","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000137/form4.xml","form_type":"4"}},{"id":1849009,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Restricted Stock Units","published_at":"2023-06-20T12:29:12.000Z","date":"2023-04-25","kind":"exercise","planned":false,"acquired":false,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted stock units (\"RSU\"), each of which represents a contingent right to receive one share of the Issuer's common stock.  The RSUs were granted on March 31, 2022, and vest as follows:  One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025.  Settlement of vested RSUs will occur as soon as practicable following vesting."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."}],"balance_after":1667,"derivative":{"underlying":"Common Shares","underlying_shares":833},"source":{"system":"sec-edgar","filing":"0000912282-23-000135","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000135/form4.xml","form_type":"4"}},{"id":1849008,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"officer":true,"officer_title":"Chief Commerical Officer"}}],"security":"Common Shares","published_at":"2023-06-20T12:29:12.000Z","date":"2023-04-25","kind":"exercise","planned":false,"acquired":true,"shares":833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects a 1:20 reverse stock split effected by the Issuer on January 4, 2023."}],"balance_after":9935,"source":{"system":"sec-edgar","filing":"0000912282-23-000135","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000091228223000135/form4.xml","form_type":"4"}},{"id":2078533,"issuer":{"id":7560,"kind":"organization","name":"AYTU BIOPHARMA, INC"},"owners":[{"id":27711,"kind":"person","name":"PYSZCZYMUKA GREG","position":1,"cik":"0001952920","reported_name":"PYSZCZYMUKA GREG","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2022-12-21T14:15:17.000Z","date":"2022-12-19","kind":"purchase","acquired":true,"shares":100000,"price":0.2448,"value":24480.0,"ownership":{"direct":true},"balance_after":182056,"source":{"system":"sec-edgar","filing":"0001567619-22-021899","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1385818/000156761922021899/doc1.xml","form_type":"4"}}]}